select a format

Single User License
USD 250 INR 16018
Site License
USD 500 INR 32035
Corporate User License
USD 750 INR 48053

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


ZIOPHARM Oncology Inc (ZIOP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

ZIOPHARM Oncology Inc (ZIOP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH24573D
  • |
  • Pages: 64
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Ziopharm Oncology Inc (Ziopharm), formerly EasyWeb Inc is a biotechnology company that discovers and develops cancer therapies. The company develops novel gene expression, control and cell technologies to provides cell-based therapies for the treatment of cancer and graft-versus-host-disease (GvHD). It offers engineering techniques and multi-genic gene programs to develop next-generation patient and donor-derived adoptive cellular therapies. Ziopharm's pipeline products include Ad-RTS-IL-12 and CAR/Cytokine Products. The company's technology platforms comprise RheoSwitch therapeutic system, UltraVector, adoptive cell therapy, ActoBiotics, AttSite Recombinases and Leap among others. Its products and technologies are used in the treatment of hematologic malignancies, solid tumors and graft-versus-host-disease. Ziopharm is headquartered in Boston, Massachusetts, the US.

ZIOPHARM Oncology Inc (ZIOP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

ZIOPHARM, Intrexon Enter into Agreement with NCI 11

Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 11

Ziopharm Expands Co-Development Agreement with Intrexon 12

Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 13

Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 15

ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 15

Licensing Agreements 17

Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 17

Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin 19

ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin 20

Equity Offering 21

ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 21

Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 22

Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 24

ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 25

ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million 26

ZIOPHARM Oncology Inc-Key Competitors 28

Key Employees 29

Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

May 01, 2017: Ziopharm Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities 31

Feb 16, 2017: ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities 34

Nov 09, 2016: ZIOPHARM Reports Third Quarter 2016 Financial Results and Provides Update on Recent Activities 36

Aug 09, 2016: ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities 39

May 10, 2016: ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities 41

Feb 24, 2016: ZIOPHARM Reports Fourth-Quarter 2015 Financial Results and Provides Update on Recent Activities 43

Legal and Regulatory 46

Jul 15, 2016: Federman & Sherwood Investigates ZIOPHARM Oncology for Possible Violations of Federal Securities Laws 46

Product News 47

11/15/2016: Sleeping Beauty System Used to Co-express CAR with Membrane-Bound IL-15 to Enhance Persistence of CD19-Specific T Cells 47

10/10/2016: ZIOPHARM Presents Data Demonstrating Activation of Anti-Tumor Immune Response Using Ad-RTS-hIL-12 in Patients with Advanced Breast Cancer 48

03/09/2016: Molecular Therapy Publication Highlights Sleeping Beauty Potential in Personalized TCR Gene Therapy 49

Feb 23, 2016: ZIOPHARM Announces Publication in Scientific Reports Describing Genetic Editing of Human Leukocyte Antigen in Cell Therapies to Broaden Their Human Application 50

Jan 11, 2016: ZIOPHARM Announces Sleeping Beauty Non-Viral Gene Transfer Technology Featured in Nature Medicine 51

Clinical Trials 52

Jan 31, 2017: ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing "Point-of-Care" Approach 52

Nov 17, 2016: ZIOPHARM Announces Clinical Data on Ad-RTS-hIL-12 Demonstrates Survival Benefits in Patients with Recurrent Brain Cancer 53

Jul 19, 2016: ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 54

Jul 15, 2016: ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 55

Jul 12, 2016: ZIOPHARM Announces Plans for Phase I Clinical Trial with CD33 CAR-T Cell Therapy Targeting Acute Myeloid Leukemia 56

Jun 27, 2016: ZIOPHARM Completes Enrollment in Second Patient Cohort and Initiates Enrollment in Third Cohort in Phase 1 Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 57

May 18, 2016: ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 58

Apr 18, 2016: ZIOPHARM Announces Oral Presentation on AdRTSIL-12 at ASGCT 19th Annual Meeting 60

Apr 18, 2016: ZIOPHARM Announces Oral Presentation on Cancer Immunotherapy at ASGCT 19th Annual Meeting 61

Feb 24, 2016: ZIOPHARM Announces First Patient Treated in the Dose Escalation Portion of the Phase I Study of Ad-RTS-hIL-12 for Advanced Glioma 62

Feb 09, 2016: ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies 63

Appendix 64

Methodology 64

About GlobalData 64

Contact Us 64

Disclaimer 64

List of Figures

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

ZIOPHARM Oncology Inc, Deals By Therapy Area, 2011 to YTD 2017 9

ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

ZIOPHARM, Intrexon Enter into Agreement with NCI 11

Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 11

Ziopharm Expands Co-Development Agreement with Intrexon 12

Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 13

Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 15

ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 15

Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 17

Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin 19

ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin 20

ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 21

Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 22

Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 24

ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 25

ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million 26

ZIOPHARM Oncology Inc, Key Competitors 28

ZIOPHARM Oncology Inc, Key Employees 29

ZIOPHARM Oncology Inc, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ZIOPHARM Oncology Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com